Fixed combination of tazarotene and betamethasone dipropionate for treatment of psoriasis vulgaris: The result of a phase 3, multicenter, randomized controlled trial
- 28 April 2020
- journal article
- research article
- Published by Wiley in The Journal of Dermatology
- Vol. 47 (7), 728-734
- https://doi.org/10.1111/1346-8138.15349
Abstract
Long‐term use of corticosteroids or local use of tazarotene (TAZ) alone for the treatment of psoriasis cause safety issues and low compliance rates. Combining these two may optimize their efficacy and minimize safety concerns. This study aimed to evaluate the clinical efficacy and safety of a fixed combination of TAZ 0.05% and betamethasone dipropionate 0.05% (BM) for psoriasis vulgaris. A multicenter, randomized, single‐blinded, controlled phase 3 clinical trial was conducted. A total of 600 Chinese subjects with psoriasis vulgaris were randomized (3:1:1) to TAZ/BM cream, TAZ gel or BM cream groups for 6 weeks with an 8‐week follow up. The primary efficacy assessment end‐point was 75% improvement in Psoriasis Area and Severity Index (PASI‐75) at 6 weeks. Secondary outcome assessments included PASI‐90, percentage of PASI decrease and so forth. Safety and treatment‐related adverse events were monitored throughout the study. Our results demonstrated that the TAZ/BM group exhibited statistically significant superiority in PASI‐75 over TAZ (6.74% vs 1.67%) within 2 weeks. After 6 weeks of treatment, PASI‐75 was 44.94% in the TAZ/BM group while 19.17% and 35.00% in the TAZ and BM group, respectively. At the 8‐week follow up, the relapse rate of the TAZ/BM group was significantly lower than the BM group (10.62% vs 29.63%, P = 0.0269) though comparable with the TAZ group (10.00%). The most frequently reported treatment‐related adverse event was mild to moderate level of skin irritation events. TAZ/BM combination has significant advantages over TAZ, including satisfying efficacy, rapid onset and reduced local stimulation. Meanwhile, compared with BM, it has the advantages of longer relief time and reduced clinical relapse rate. The TAZ/BM combination drug provides psoriatic patients an alternative drug with high efficacy and low relapse rate and safety concerns.Keywords
Funding Information
- Major new drugs creation, Major science, and technology program, Sub-project of “Chongqing Drug Innovation Incubator Base” (2010ZX09401-306-2-17)
This publication has 17 references indexed in Scilit:
- Topical steroid risk analysis: Differentiating between physiologic and pathologic adrenal suppressionJournal of Dermatological Treatment, 2013
- Psoriasis Severity and the Prevalence of Major Medical ComorbidityJAMA Dermatology, 2013
- PsoriasisThe New England Journal of Medicine, 2009
- Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapiesJournal of the American Academy of Dermatology, 2009
- Psoriasis: epidemiologyClinics in Dermatology, 2007
- Psoriasis: genetic associations and immune system changesGenes & Immunity, 2006
- Psoriasis Is Common, Carries a Substantial Burden Even When Not Extensive, and Is Associated with Widespread Treatment DissatisfactionJournal of Investigative Dermatology Symposium Proceedings, 2004
- Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeksJournal of the American Academy of Dermatology, 2003
- Duration of improvement in psoriasis after treatment with tazarotene 0.1% gel plus clobetasol propionate 0.05% ointment: comparison of maintenance treatmentsInternational Journal of Dermatology, 2001
- TazaroteneDrugs, 1998